The Supreme Court ruled to uphold a new process for challenging patents that the pharmaceutical industry was hoping would be struck down, according to an article in AJMC. Pharmaceutical manufacturers argued that the rule would stifle innovation and endanger investments in drug research and development.
The Supreme Court delivered a unanimous opinion, the article said.
“The regulation is a reasonable exercise of the Patent Office’s rulemaking authority,” Justice Stephen Breyer wrote in the Court’s opinion. “The broadest reasonable construction standard helps ensure precision in drafting claims and prevents a patent from tying up too much knowledge, which, in turn, helps members of the public draw useful information from the disclosed invention and understand the lawful limits of the claim.”
Read the full article